Importer of Controlled Substances Application: Caligor Coghlan Pharma Services, 84166-84167 [2023-26558]
Download as PDF
<![CDATA[
84166
Federal Register / Vol. 88, No. 231 / Monday, December 4, 2023 / Notices
membership, which is bound by Indian
Preference Act of 1990 (25 U.S.C. 472).
5. Basis for Nominations
If you wish to nominate someone for
appointment to the Advisory Board,
please do not make the nomination until
the person has agreed to have his or her
name submitted to the BIE for this
purpose. A person can also selfnominate.
6. Nomination Application
Please submit a complete application
form and a copy of the nominee’s
resume or curriculum vitae to the DFO
by Wednesday, January 31, 2024. The
nomination application form can be
found on the BIE website at https://
www.bie.edu/sites/default/files/inlinefiles/Advisory-Board-MembershipNomination-Form%20%28Expires
%206-30-24%29.pdf.
7. Information Collection
This collection of information is
authorized by OMB Control Number
1076–0179, ‘‘Solicitation of
Nominations for the Advisory Board for
Exceptional Children,’’ with a June 30,
2024, expiration date.
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on November 1, 2023,
Element Materials Technology Santa
Rosa, 3331 Industrial Drive, Suite B,
Santa Rosa, California 95403–2062,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
ADDRESSES:
Drug
code
Controlled substance
(Authority: 5 U.S.C. ch. 10; 20 U.S.C. 1400
et seq.)
Oxymorphone .............
Fentanyl .....................
Bryan Newland,
Assistant Secretary—Indian Affairs.
I
9652
9801
Schedule
I
II
II
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of the listed controlled
substances in bulk form. No other
activities for these drug codes are
authorized for this registration.
[FR Doc. 2023–26518 Filed 12–1–23; 8:45 am]
BILLING CODE 4337–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1304]
Claude Redd,
Acting Deputy Assistant Administrator.
Bulk Manufacturer of Controlled
Substances Application: Element
Materials Technology Santa Rosa
[FR Doc. 2023–26553 Filed 12–1–23; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Element Materials
Technology Santa Rosa has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before February 2, 2024. Such
persons may also file a written request
for a hearing on the application on or
before February 2, 2024.
ddrumheller on DSK120RN23PROD with NOTICES1
19:20 Dec 01, 2023
Jkt 262001
Drug
code
Controlled substance
SUMMARY:
VerDate Sep<11>2014
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before January 3, 2024. Such
persons may also file a written request
for a hearing on the application on or
before January 3, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on October 13, 2023,
Caligor Coghlan Pharma Services, 1500
Business Park Drive, Unit B, Bastrop,
Texas 78602, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
DATES:
[Docket No. DEA–1300]
Importer of Controlled Substances
Application: Caligor Coghlan Pharma
Services
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Caligor Coghlan Pharma
Services, has applied to be registered as
an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Dimethyltryptamine ....
I
7435
Schedule
II
The company plans to import the
listed controlled substance as finished
dosage units for use in clinical trials. No
other activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or non-
E:\FR\FM\04DEN1.SGM
04DEN1
84167
Federal Register / Vol. 88, No. 231 / Monday, December 4, 2023 / Notices
approved finished dosage forms for
commercial sale.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before January 3, 2024. Such
persons may also file a written request
for a hearing on the application on or
before January 3, 2024.
DATES:
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–26558 Filed 12–1–23; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[Docket No. DEA–1305]
Importer of Controlled Substances
Application: Restek Corporation
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Restek Corporation has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
SUMMARY:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
ADDRESSES:
Drug Enforcement Administration
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on November 6, 2023,
Restek Corporation, 110 Benner Circle,
Bellefonte, Pennsylvania 16823–8433,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug
code
ddrumheller on DSK120RN23PROD with NOTICES1
Controlled substance
Amineptine ...................................................................................................................................................................................
Mesocarb .....................................................................................................................................................................................
3-Fluoro-N-methylcathinone (3–FMC) .........................................................................................................................................
Cathinone ....................................................................................................................................................................................
Methcathinone .............................................................................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) .........................................................................................................................................
Para-Methoxymethamphetamine (PMMA), 1-(4-1245 I N methoxyphenyl)-N-methylpropan-2-amine .......................................
Pentedrone (a-methylaminovalerophenone) ...............................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ................................................................................................................................
4-Methyl-N-ethylcathinone (4–MEC) ...........................................................................................................................................
Naphyrone ...................................................................................................................................................................................
N-Ethylamphetamine ...................................................................................................................................................................
Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-1478 I N amine) ...................................................................................
N,N-Dimethylamphetamine ..........................................................................................................................................................
Fenethylline .................................................................................................................................................................................
Aminorex ......................................................................................................................................................................................
4-Methylaminorex (cis isomer) ....................................................................................................................................................
4,4′-Dimethylaminorex .................................................................................................................................................................
Gamma Hydroxybutyric Acid .......................................................................................................................................................
Methaqualone ..............................................................................................................................................................................
Mecloqualone ..............................................................................................................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ..............................................................................................................
SR–18 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) 7008 I N SR–18 and RCS–8 indole) SR–19 (1–P ...............................
ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .........................
5-Fluoro-UR–144 and XLR11 ([1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone) .........................
AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .................................
1-(4-Fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-7014 I N FUB–144 tetramethylcyclopropyl)methanone .............................................
JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ..................................................................................................................................
MDMB–FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ..................................
FUB–AMB, MMB–FUBINACA, AMB–FUBINACA (2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3-methylbutanoate) ......
AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-)3-carboxamide .....................................................
THJ–2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) .............................................................................
5F–AB–PINACA (N-(1-amino-3methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ..................................
AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ...........................
MAB–CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ....................
5F–AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ..........................................................
5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ..................
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .............................................
Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido) 3,3-dimethylbutanoate) .......................................................................
5F–MDMB–PICA .........................................................................................................................................................................
MDMB–CHMICA, MMB–CHMINACA ..........................................................................................................................................
Methyl 2–7043 I N (1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3dimethylbutanoate) ........................................................
MMB–CHMICA ............................................................................................................................................................................
FUB–AKB48; FUB–APINACA; AKB48 N-(4–FLUOROBENZYL) ...............................................................................................
VerDate Sep<11>2014
19:20 Dec 01, 2023
Jkt 262001
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
E:\FR\FM\04DEN1.SGM
04DEN1
1219
1227
1233
1235
1237
1238
1245
1246
1248
1249
1258
1475
1478
1480
1503
1585
1590
1595
2010
2565
2572
6250
7008
7010
7011
7012
7014
7019
7020
7021
7023
7024
7025
7031
7032
7033
7034
7035
7036
7041
7042
7043
7044
7047
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 88, Number 231 (Monday, December 4, 2023)]
[Notices]
[Pages 84166-84167]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26558]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1300]
Importer of Controlled Substances Application: Caligor Coghlan
Pharma Services
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Caligor Coghlan Pharma Services, has applied to be registered
as an importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
January 3, 2024. Such persons may also file a written request for a
hearing on the application on or before January 3, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on October 13, 2023, Caligor Coghlan Pharma Services,
1500 Business Park Drive, Unit B, Bastrop, Texas 78602, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Dimethyltryptamine.................... 7435 I
------------------------------------------------------------------------
The company plans to import the listed controlled substance as
finished dosage units for use in clinical trials. No other activities
for these drug codes are authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-
[[Page 84167]]
approved finished dosage forms for commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-26558 Filed 12-1-23; 8:45 am]
BILLING CODE 4410-09-P
